METHOD FOR BONE MARROW PRESERVATION OR RECOVERY

• US 20100278778A1
• Filed: 04/08/2010
• Published: 11/04/2010
• Est. Priority Date: 07/03/2003
• Status: Active Grant

• Current Assignee: University of Southern California
• Original Assignee: University of Southern California
• Inventors: Zhao, Yi, Anderson, W. French, Chen, Tingchao
• Granted Patent: US 9,402,882 B2
• Time in Patent Office: Days
• US Class Current: 424/85.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 2005/1098 Enhancing the effect of the particle by an injected agent or implanted device
• CPC Class Codes: A61N 5/10 X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy A61N5/01 takes precedence
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 14/53 Colony-stimulating factor [CSF]
• CPC Class Codes: C07K 14/5434 IL-12

Abstract

Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.

Claims

1. A method for bone marrow preservation or recovery in a mammal comprising administering one or more therapeutically effective dose(s) of IL-12 to the mammal, without the use of hemtopoietic repopulating cells, hematopoietic progenitor cells or hematopoietic stem cells, for a duration necessary for bone marrow preservation or recovery.

2. The method of claim 1, wherein the mammal has bone marrow failure.

3. The method of claim 1, wherein the mammal is suffering from a disease state and near destruction of the bone marrow is a by-product of a treatment regimen to combat the disease state.

4. The method of claim 1, wherein the administration of therapeutically effective doses of IL-12 for a duration necessary for bone marrow preservation or recovery, obviates the need for a bone marrow transplant.

5. The method of claim 1, wherein bone marrow preservation or recovery includes an increase in hematopoietic repopulating cell, hematopoietic stem cells or hematopoietic progenitor cells.

6. The method of claim 1, wherein bone marrow preservation or recovery includes an increase in one or more differentiated hematopoietic cells types.

7. The method of claim 1, wherein bone marrow preservation or recovery includes an increase in hematopoietic support cells.

8. The method of claim 1, wherein the mammal has a deficiency in one or more hematopoietic cell types or lineages.

9. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising lymphopenia.

10. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising myelopenia.

11. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising leukopenia.

12. The method of claim 11, wherein the leukopenia is neutropenia.

13. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising a erythropenia.

14. The method of claim 1, wherein the mammal has a deficiency comprising megakaryopenia.

15. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising a deficiency in platelets.

16. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising a deficiency in monocytes.

17. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising a deficiency in lymphocyctes.

18. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising a deficiency in erythrocytes.

19. The method of claim 1, wherein the mammal has a hematopoietic deficiency comprising a deficiency in neutrophils.

20. The method of claim 1, wherein the mammal in need has a hematopoietic deficiency comprising a deficiency in T cells.

21. The method of claim 1, wherein the mammal in need has a hematopoietic deficiency comprising a deficiency in granulocytes.

22. The method of claim 1, wherein the mammal in need has a hematopoietic deficiency comprising a deficiency in dendritic cells.

23. The method of claim 1, wherein the dose of IL-12 is less than about 2000 ng/kg.

24. The method of claim 1, wherein the dose of IL-12 is less than about 500 ng/kg.

25. The method of claim 1, wherein the dose of IL-12 is less than about 100 ng/kg.

26. The method of claim 1, wherein the dose of IL-12 is less than about 10 ng/kg.